Literature DB >> 25230753

IL-5 triggers a cooperative cytokine network that promotes eosinophil precursor maturation.

Patricia C Fulkerson1, Kaila L Schollaert1, Carine Bouffi1, Marc E Rothenberg2.   

Abstract

Eosinophils originate in the bone marrow from an eosinophil lineage-committed, IL-5Rα-positive, hematopoietic progenitor (eosinophil progenitor). Indeed, IL-5 is recognized as a critical regulator of eosinophilia and has effects on eosinophil progenitors, eosinophil precursors, and mature eosinophils. However, substantial levels of eosinophils remain after IL-5 neutralization or genetic deletion, suggesting that there are alternative pathways for promoting eosinophilia. In this study, we investigated the contributory role of IL-5 accessory cytokines on the final stages of eosinophil differentiation. IL-5 stimulation of low-density bone marrow cells resulted in expression of a panel of cytokines and cytokine receptors, including several ligand-receptor pairs. Notably, IL-4 and IL-4Rα were expressed by eosinophil precursors and mature eosinophils. Signaling through IL-4Rα promoted eosinophil maturation when IL-5 was present, but IL-4 stimulation in the absence of IL-5 resulted in impaired eosinophil survival, suggesting that IL-4 cooperates with IL-5 to promote eosinophil differentiation. In contrast, CCL3, an eosinophil precursor-produced chemokine that signals through CCR1, promotes terminal differentiation of CCR1-positive eosinophil precursors in the absence of IL-5, highlighting an autocrine loop capable of sustaining eosinophil differentiation. These findings suggest that brief exposure to IL-5 is sufficient to initiate a cytokine cooperative network that promotes eosinophil differentiation of low-density bone marrow cells independent of further IL-5 stimulation.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25230753      PMCID: PMC4185228          DOI: 10.4049/jimmunol.1400732

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.

Authors:  Sabine-Gisela Plötz; Hans-Uwe Simon; Ulf Darsow; Dagmar Simon; Ekatherina Vassina; Shida Yousefi; Rüdiger Hein; Tim Smith; Heidrun Behrendt; Johannes Ring
Journal:  N Engl J Med       Date:  2003-12-11       Impact factor: 91.245

2.  CD34(+)/interleukin-5Ralpha messenger RNA+ cells in the bronchial mucosa in asthma: potential airway eosinophil progenitors.

Authors:  D S Robinson; R Damia; K Zeibecoglou; S Molet; J North; T Yamada; A B Kay; Q Hamid
Journal:  Am J Respir Cell Mol Biol       Date:  1999-01       Impact factor: 6.914

3.  Rapid increase in bone-marrow eosinophil production and responses to eosinopoietic interleukins triggered by intranasal allergen challenge.

Authors:  M I Gaspar Elsas; D Joseph; P X Elsas; B B Vargaftig
Journal:  Am J Respir Cell Mol Biol       Date:  1997-10       Impact factor: 6.914

4.  IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses.

Authors:  M Kopf; F Brombacher; P D Hodgkin; A J Ramsay; E A Milbourne; W J Dai; K S Ovington; C A Behm; G Köhler; I G Young; K I Matthaei
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

5.  Variations in eosinophil chemokine responses: an investigation of CCR1 and CCR3 function, expression in atopy, and identification of a functional CCR1 promoter.

Authors:  Rhian M Phillips; Victoria E L Stubbs; Mandy R Henson; Timothy J Williams; James E Pease; Ian Sabroe
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

6.  Increased MCP-1, RANTES, and MIP-1alpha in bronchoalveolar lavage fluid of allergic asthmatic patients.

Authors:  R Alam; J York; M Boyars; S Stafford; J A Grant; J Lee; P Forsythe; T Sim; N Ida
Journal:  Am J Respir Crit Care Med       Date:  1996-04       Impact factor: 21.405

7.  Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF.

Authors:  E J Clutterbuck; E M Hirst; C J Sanderson
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

8.  Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses.

Authors:  G J McKenzie; P G Fallon; C L Emson; R K Grencis; A N McKenzie
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

9.  Dominant myelopoietic effector functions mediated by chemokine receptor CCR1.

Authors:  H E Broxmeyer; S Cooper; G Hangoc; J L Gao; P M Murphy
Journal:  J Exp Med       Date:  1999-06-21       Impact factor: 14.307

10.  Eosinophilia in transgenic mice expressing interleukin 5.

Authors:  L A Dent; M Strath; A L Mellor; C J Sanderson
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

View more
  35 in total

1.  Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.

Authors:  Sandhya R Panch; Michael E Bozik; Thomas Brown; Michelle Makiya; Calman Prussin; Donald G Archibald; Gregory T Hebrank; Mary Sullivan; Xiaoping Sun; Lauren Wetzler; JeanAnne Ware; Michael P Fay; Cynthia E Dunbar; Steven I Dworetzky; Paneez Khoury; Irina Maric; Amy D Klion
Journal:  Blood       Date:  2018-05-08       Impact factor: 22.113

Review 2.  Biological therapies for eosinophilic gastrointestinal diseases.

Authors:  Joshua B Wechsler; Ikuo Hirano
Journal:  J Allergy Clin Immunol       Date:  2018-05-31       Impact factor: 10.793

Review 3.  Biologic therapies targeting eosinophils: current status and future prospects.

Authors:  Fanny Legrand; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

Review 4.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

5.  Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia.

Authors:  Kristina Johansson; Carina Malmhäll; Patricia Ramos-Ramírez; Madeleine Rådinger
Journal:  Immunology       Date:  2017-10-19       Impact factor: 7.397

6.  IL-33 mediates reactive eosinophilopoiesis in response to airborne allergen exposure.

Authors:  E L Anderson; T Kobayashi; K Iijima; K R Bartemes; C-C Chen; H Kita
Journal:  Allergy       Date:  2016-03-02       Impact factor: 13.146

7.  Whole-exome sequencing uncovers oxidoreductases DHTKD1 and OGDHL as linkers between mitochondrial dysfunction and eosinophilic esophagitis.

Authors:  Joseph D Sherrill; Kiran Kc; Xinjian Wang; Ting Wen; Adam Chamberlin; Emily M Stucke; Margaret H Collins; J Pablo Abonia; Yanyan Peng; Qiang Wu; Philip E Putnam; Phillip J Dexheimer; Bruce J Aronow; Leah C Kottyan; Kenneth M Kaufman; John B Harley; Taosheng Huang; Marc E Rothenberg
Journal:  JCI Insight       Date:  2018-04-19

8.  Reuse of public, genome-wide, murine eosinophil expression data for hypotheses development.

Authors:  Jillian O Grace; Astha Malik; Hadar Reichman; Ariel Munitz; Artem Barski; Patricia C Fulkerson
Journal:  J Leukoc Biol       Date:  2018-05-14       Impact factor: 4.962

Review 9.  Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Maria Gabriella Matera; Clive Page; Paola Rogliani; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

10.  Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort.

Authors:  Julia L M Dunn; Tetsuo Shoda; Julie M Caldwell; Ting Wen; Seema S Aceves; Margaret H Collins; Evan S Dellon; Gary W Falk; John Leung; Lisa J Martin; Paul Menard-Katcher; Amanda K Rudman-Spergel; Jonathan M Spergel; Joshua B Wechsler; Guang-Yu Yang; Glenn T Furuta; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.